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LETTER
Prevalent low-grade dysplasia:




Dear Professor Emad El-Omar,
We read with interest the work by Duits
et al1 who ﬁnd that validated low-grade
dysplasia (LGD) is highly predictive of
malignant progression in Barrett’s
oesophagus (BO). Yachimski2 stresses the
need for this important ﬁnding to be vali-
dated in other centres. Our experience of
prevalent LGD as a predictor of malignant
progression in BO in the West of Scotland
strongly reinforces the conclusions of our
colleagues in the Netherlands.
Patients with BO diagnosed between
1994 and 2009 at one centre (Glasgow
Royal Inﬁrmary (GRI)) all had BO visible
endoscopically, with biopsy-proven meta-
plastic glandular mucosa in the tubular
oesophagus. Exclusions for residence
outside GRI catchment area, severe
comorbidities, refusal of surveillance, loss
to follow-up, high-grade dysplasia (HGD)
or oesophageal adenocarcinoma (OA) at
diagnosis (or ascertained within 1 year of
index endoscopy), or being indeﬁnite for
dysplasia (n=15) left 145 short (≤3 cm)
and 577 long (>3 cm) patients with BO
in surveillance.
Biopsy protocol was by endoscopist’s
choice. Endoscopy was biennial without
LGD, and 3–6 monthly after LGD ascer-
tainment. Patients with new HGD or OA
were offered endoscopic treatment or
surgery. Proton pump inhibitors (PPIs)
were prescribed throughout. Death and its
causes were ascertained from the regional
registrar. Follow-up was from entry to
progression, death or 31 December 2012.
Age and BO length thresholds were
taken as <65, 65–74, >75 years; ≤3 cm,
>3 cm. Progression-free survival was exam-
ined with the Kaplan–Meier estimator and
Cox’s proportional hazards regression of
progression to HGD or OAwith the follow-
ing factors: prevalent dysplasia as originally
reported, age, gender, segment length and
social deprivation, using R V.3.0.2, with
libraries survival andmuhaz.
Our 722-person cohort of 437 men
(1st quartile:median:3rd quartile
53:63:72 years) and 285 women
(61:69:78 years) underwent 74 989
months’ follow-up (75:109:137 months).
N=58 patients with prevalent dysplasia
were slightly older (median 67 vs
64 years, p<0.05) and more likely to be
male (40 men, 18 women, p<0.02). Of
these 58, 21 (36%) progressed to HGD
(9) or OA (12) at overall rates of 2.0%
and 2.7% per annum, respectively
(p<0.001).
Of the 664 patients without identiﬁed
prevalent dysplasia, 85 progressed:
54 (8%) to LGD at 0.93% per annum.
Only 10 (1.5%) developed HGD at
0.17% per annum and 21 (3.2%) OA, at
0.36% per annum. LGD was powerfully
predictive of progression, with HR 10.8
(95% CI 5.9 to 18.1) for progression to
HGD and 7.3 (95% CI 3.6 to 14.7) for
progression to OA. No other factor was
prognostic independent of LGD.
Figure 1A shows malignant progression
(to HGD/OA) stratiﬁed by prevalent LGD
status. Comparison with ﬁgure 3 of Duits
et al1 shows an identical proportion of
patients with LGD with malignant pro-
gression in our cohort and in the Dutch
cohort (ﬁgure 1B).
Our patients with BO and prevalent
LGD had a 10-fold hazard of progression
to HGD and sevenfold to OA compared
with those without dysplasia. Kaplan–
Meier plots for progression to HGD/OA
in our patients with LGD and those vali-
dated by Duits et al are almost identical:
this is good evidence that what we call
LGD in Glasgow and what our expert col-
leagues in Amsterdam and Nieuwegein
call LGD are indeed the same.
Our analysis is of histopathology reports
as originally issued by reporting patholo-
gist(s), but throughout the study period,
specialist GI pathologists, AKF, JJG and
KAO, were readily available to colleagues
for discussion and case review. We are not
special, and we think any motivated group
of GI histopathologists should achieve risk
stratiﬁcation equally good or better. We
strongly endorse present recommendations
for peer review and audit of dysplasia diag-
noses in BO.3 Radiofrequency ablation
(RFA) prevents progression of LGD in
BO,4 but it is not universally accepted that
malignant progression occurs often
enough in LGD to justify RFA. We think
validated LGD (purged of spurious diag-
noses) is a genuine marker of high progres-
sion risk in BO, which should be actively
sought in new BO cases and when found,
should be treated.
Lisa H Moyes,1 Karin A Oien,2,3 Alan K Foulis,2
Grant M Fullarton,1 James J Going2,3
1Department of Surgery, Glasgow Royal Inﬁrmary,
Glasgow, UK
Figure1 (A) Kaplan–Meier curves for malignant progression (to HGD and/or OA) in Glasgow BO
cases with prevalent LGD (red curve) and without (blue). Grey shading represents 95% CI. Numbers
in follow-up are given above the x axis. (B) duplicates the ﬁrst 5 years of these curves and
superimposes (in orange) the curve for malignant progression of LGD, validated by Duits et al1 in the
Netherlands. The LGD curves are very close at 5 years. BO, Barrett’s oesophagus; HGD, high-grade
dysplasia; LGD, low-grade dysplasia; NL, Netherlands; OA, oesophageal adenocarcinoma.
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